Marketing


  • Anne Wojcicki speaking event
    Image attribution tooltip
    Brad Barket via Getty Images
    Image attribution tooltip

    23andMe CEO plans to take company private

    Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

    By Elise Reuter • April 18, 2024
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Stelara biosimilar from Alvotech, Teva approved by FDA

    The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

    By Kristin Jensen • April 17, 2024
  • Explore the Trendline
    Image attribution tooltip
    Brian Tucker / BioPharma Blog
    Image attribution tooltip
    Trendline

    Pharma, new drugs and market strategy

    New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

    By BioPharma Blog staff
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche reports survival data for new dual-acting lymphoma drug

    The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

    By April 15, 2024
  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    European regulator concludes no suicide link to obesity drugs

    The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

    By April 12, 2024
  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US sues Regeneron, alleging false price reporting on Eylea

    The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

    By Kristin Jensen • April 11, 2024
  • FDA rejects Regeneron lymphoma drug, setting back company’s oncology push

    The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

    By March 25, 2024
  • Doctor hands texting on a smart phone
    Image attribution tooltip

    shutterstock.com/VAlekStudio

    Image attribution tooltip
    Sponsored by Veeva

    Give HCPs a proactive way to reach your field team: Add inbound

    HCPs today want inbound channels for help when they need it. See how you can meet their preferences.

    By Paul Shawah, Executive Vice President of Strategy, Veeva • March 18, 2024
  • The East facade of the Capitol Building in Washington DC.
    Image attribution tooltip
    dkfielding via Getty Images
    Image attribution tooltip

    BIO changes stance, backs bill to limit China’s role in US biotech

    Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with WuXi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

    By March 14, 2024
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    After surprise trial failure, ALS doctors brace for one less treatment option

    Physicians have been preparing for tough conversations with patients on Amylyx's drug since negative confirmatory trial results in March.

    By Updated April 4, 2024
  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    Novavax agrees to pay Gavi in settlement over COVID vaccine contract

    Under the deal’s terms, Novavax will pay the vaccine alliance up to $475 million over five years.

    By Kristin Jensen • Feb. 22, 2024
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Ipsen drug approved by FDA for early pancreatic cancer

    The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

    By Feb. 14, 2024
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen has a fuzzy line of sight on prized Alzheimer’s drug

    CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.

    By Feb. 13, 2024
  • Compass on rocks with a dark sky
    Image attribution tooltip

    stock.adobe.com//ergregory

    Image attribution tooltip
    Sponsored by Alexander Group

    Chart a course for sustainable growth

    Explore how companies are optimizing efficiency, enhancing customer experiences and embracing AI.

    Feb. 12, 2024
  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai falls behind on Leqembi patient goal

    The Alzheimer’s drug was administered to a total of 2,000 U.S. patients as of Jan. 26, signaling to analysts that an earlier goal of 10,000 may take longer than expected to hit.

    By Feb. 6, 2024
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen quits Aduhelm, handing back rights to original developer

    The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

    By Jan. 31, 2024
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA orders new cancer warnings for CAR-T therapies

    The agency later modified its warning for Gilead's Tecartus, tweaking the label's language to reflect the fact that none of T cell malignancies in question had occurred in Tecartus-treated patients.

    By Updated Jan. 24, 2024
  • Ajay Purohit, a Biogen employee, points to brain scans of people with Alzheimer's
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

    At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

    By Jan. 8, 2024
  • A Lilly sign is seen on the side of a building viewed through pine trees
    Image attribution tooltip
    jetcityimage via Getty Images
    Image attribution tooltip

    Lilly launches online service for home delivery of weight loss drug

    The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.

    By Jan. 4, 2024
  • Highway at sunset
    Image attribution tooltip

    stock.adobe.com/LeveL4

    Image attribution tooltip
    Sponsored by Alexander Group

    Profitable growth is on the horizon

    A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.

    Dec. 11, 2023
  • CVS storefront
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    CVS overhauls how its retail pharmacies charge for prescription drugs

    Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.

    By Rebecca Pifer • Dec. 5, 2023
  • The European Union flag.
    Image attribution tooltip
    artJazz via Getty Images
    Image attribution tooltip
    Obesity drugs

    European regulators want to know more about the risks of GLP-1 drugs

    The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.

    By Dec. 1, 2023
  • A Cigna logo behind a construction fence.
    Image attribution tooltip

    Matt Slocum/AP

    Image attribution tooltip

    Cigna, Humana in talks to merge: WSJ

    The merger would have major effects for the makeup of the U.S. health insurance industry, and would almost certainly face a regulatory challenge.

    By Rebecca Pifer • Nov. 29, 2023
  • A building in front of a pond with the sign "Medtronic" on a stone wall.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic CEO downplays impact of obesity drugs on procedures, devices

    Surging demand for GLP-1 agonists has put medtech firms like Medtronic under pressure, even as they argue the hit to their businesses will be minimal.

    By Ricky Zipp • Nov. 21, 2023
  • A photograph of an infusion bag of Abecma, a cell therapy from Bristol Myers Squibb and 2seventy bio
    Image attribution tooltip
    Courtesy of Bristol Myers Squibb
    Image attribution tooltip

    Bristol Myers faces FDA delay on cancer cell therapy decision

    The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.

    By Nov. 20, 2023
  • Boxes of the diabetes drug Ozempic are seen on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    New AMA policies target GLP-1 coverage, corporate medicine

    The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.

    By Susanna Vogel • Nov. 14, 2023